

PRESS RELEASE

Free Float of BRAIN share successfully increased

Zwingenberg, February 9, 2017: Yesterday evening, B.R.A.I.N. Biotechnology Research and Information Network AG ("BRAIN AG", ISIN DE0005203947 / WKN 520394) was informed that after the end of the one-year lock-up period, MIG Fonds, as existing shareholders of the company, sold its entire stake of 2,528,389 shares to more than 20 institutional investors. The placement took place outside the stock market as part of an accelerated book-building process. The transaction, which was oversubscribed several times, was accompanied by ODDO SEYDLER BANK AG and Baader Bank AG. The free float of BRAIN shares increased from 22% to 37%.

Dr Jürgen Eck, CEO of BRAIN AG, is pleased about the strong demand from investor interest for the BRAIN share: "The MiG funds are early-stage investors, which provide venture capital for founders and young companies. They have financially supported the development of BRAIN AG for many years and have thus also contributed significantly to our success. I would therefore like to expressly thank you for the excellent and trustworthy cooperation in recent years. The high demand on the part of the investors is a further confirmation of our operating business."

"As a result of the placement, the free float of BRAIN share has significantly increased, which will also improve the tradability of the share for all investors. I am satisfied that based on the high demand from investors, a successful transaction for the MiG funds could be

Contact:

B·R·A·I·N
Biotechnology Research
And Information Network AG
Dr. Martin Langer
Executive Vice President
Corporate Development
Darmstädter Str. 34-36
64673 Zwingenberg, Germany

Tel.: +49-6251-9331-16
Fax: +49-6251-9331-11
E-Mail: ir@brain-biotech.de
www.brain-biotech.de

B•R•A•I•N

carried out as Joint Global Coordinator by the accompanying banks ODDO SEYDLER BANK AG together with BAADER BANK AG as joint bookrunners", says Frank Goebel, Member of the Management Board of BRAIN AG.

About BRAIN

BRAIN is one of Europe's leading technology companies in the field of industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN identifies previously untapped, efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by help of this "Toolbox of Nature" are successfully applied in the chemistry, the cosmetics and the food industries. Today, BRAIN's business model is based on two pillars – "BioScience" and "BioIndustrial". The first pillar, "BioScience", comprises its – frequently exclusive – collaboration business with industrial partners. The second pillar "BioIndustrial" comprises the development and commercialisation of BRAIN's own products and active product components. Further information is available at www.brain-biotech.de/en

Disclaimer

This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN AG and are based on information currently available to the management. Forward-looking statements are not guarantees of future performance and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. There are numerous factors which could influence the future performance by and future developments at BRAIN AG and the BRAIN group of companies. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, and other factors. BRAIN AG does not undertake any obligation to update or revise any forward-looking statements.